Zealand Pharma intensifies partner hunt for other drug candidates

On Wednesday, the Danish biotech firm struck a deal with Novo Nordisk, giving the giant the commercial rights to its rescue pen, and it is now looking for similar agreements with other parties, says CEO Adam Steensberg.

Photo: Zealand Pharma / PR

Zealand Pharma’s newly inked deal with Novo Nordisk is just one of many that the Danish biotech company intends to sign over the next few years. In March, Zealand Pharma changed its strategy to focus on research and development, choosing to let other companies take charge of future commercialization efforts.

The pivot followed the company’s realization that building a sales organization is a costly affair, which is why Zealand Pharma sold the rights earlier this year for its insulin pump, V-Go, for USD 10m to Mannkind, and on Wednesday traded the rights rights to rescue pen Zegalogue (dasiglucagon) with Novo Nordisk in a deal that cold run up to DKK 290m (USD 38.7m) when future milestones are counted.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs